Cargando…
461. COVID-19 Hospitalizations among Vaccinated and Unvaccinated Immunocompromised Children, 23 States, December 2022 – April 2023
BACKGROUND: Immunocompromised (IC) persons are at increased risk of severe COVID-19 and can have a suboptimal immune response to a primary 2-dose COVID-19 vaccine series; thus, vaccination recommendations for IC persons include additional COVID-19 vaccine doses. We describe outcomes and vaccination...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679127/ http://dx.doi.org/10.1093/ofid/ofad500.531 |
_version_ | 1785150520675008512 |
---|---|
author | Campbell, Angela P Zambrano, Laura D Newhams, Margaret M Wu, Michael J Simeone, Regina Orzel, Amber Halasa, Natasha B Fleming-Dutra, Katherine E Randolph, Adrienne G |
author_facet | Campbell, Angela P Zambrano, Laura D Newhams, Margaret M Wu, Michael J Simeone, Regina Orzel, Amber Halasa, Natasha B Fleming-Dutra, Katherine E Randolph, Adrienne G |
author_sort | Campbell, Angela P |
collection | PubMed |
description | BACKGROUND: Immunocompromised (IC) persons are at increased risk of severe COVID-19 and can have a suboptimal immune response to a primary 2-dose COVID-19 vaccine series; thus, vaccination recommendations for IC persons include additional COVID-19 vaccine doses. We describe outcomes and vaccination status among US IC children hospitalized with laboratory-confirmed COVID-19 during a period of SARS-CoV-2 Omicron circulation. METHODS: Children with and without an IC condition hospitalized for COVID-19 were enrolled as case-patients into a vaccine effectiveness investigation as part of the Overcoming COVID-19 network of 31 hospitals across 23 states. Data on IC conditions abstracted from the medical record included the presence of an “active or prior oncologic disorder” or a “non-oncologic immunosuppressive disorder.” Results for IC case-patients with COVID-19 enrolled from 12/18/2022–4/3/2023 (Omicron period) were analyzed by age group and vaccination status. RESULTS: Of 239 IC case-patients, 127 (53%) had an oncologic disorder and 112 (47%) non-oncologic; 120 (50%) had > 1 additional underlying medical condition (Table 1). Thirty (13%) IC case-patients were aged 8 months–4 years, 115 (48%) 5–11 years, and 94 (39%) 12–18 years. Life-threatening illness or death occurred in 1 (3%) IC case-patient aged 8 months–4 years, 8 (7%) aged 5–11 years , and 13 (14%) aged 12-18 years (including 2 deaths). Among 209 IC case-patients aged 5–18 years, 26 (23%) of those with oncologic and 27 (28%) with non-oncologic disorders had received 2 doses of a monovalent primary COVID-19 vaccine series; 6 (5%) and 14 (14%) had received > 3 doses, respectively (p=.03; Table 2). A significantly higher proportion of IC case-patients (n=73/209; 35%) had received at least 2 COVID-19 vaccine doses compared with non-IC patients (n=284/1021; 28%; p=0.04; Table 2). [Figure: see text] [Figure: see text] CONCLUSION: During Omicron, immunocompromised children hospitalized for COVID-19 were more frequently aged > 5 years and > 99% survived. Vaccination coverage was low among all case-patients. A higher proportion of IC children who received >2 vaccine doses were among those case-patients hospitalized for COVID-19 compared with non-IC children. Additional doses to improve protection in IC children are recommended. DISCLOSURES: Regina Simeone, PhD, Pfizer: Stocks/Bonds Natasha B. Halasa, MD, MPH, Merck: Grant/Research Support|Quidell: Grant/Research Support|Quidell: donation of kits|Sanofi: Grant/Research Support|Sanofi: vaccine support |
format | Online Article Text |
id | pubmed-10679127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106791272023-11-27 461. COVID-19 Hospitalizations among Vaccinated and Unvaccinated Immunocompromised Children, 23 States, December 2022 – April 2023 Campbell, Angela P Zambrano, Laura D Newhams, Margaret M Wu, Michael J Simeone, Regina Orzel, Amber Halasa, Natasha B Fleming-Dutra, Katherine E Randolph, Adrienne G Open Forum Infect Dis Abstract BACKGROUND: Immunocompromised (IC) persons are at increased risk of severe COVID-19 and can have a suboptimal immune response to a primary 2-dose COVID-19 vaccine series; thus, vaccination recommendations for IC persons include additional COVID-19 vaccine doses. We describe outcomes and vaccination status among US IC children hospitalized with laboratory-confirmed COVID-19 during a period of SARS-CoV-2 Omicron circulation. METHODS: Children with and without an IC condition hospitalized for COVID-19 were enrolled as case-patients into a vaccine effectiveness investigation as part of the Overcoming COVID-19 network of 31 hospitals across 23 states. Data on IC conditions abstracted from the medical record included the presence of an “active or prior oncologic disorder” or a “non-oncologic immunosuppressive disorder.” Results for IC case-patients with COVID-19 enrolled from 12/18/2022–4/3/2023 (Omicron period) were analyzed by age group and vaccination status. RESULTS: Of 239 IC case-patients, 127 (53%) had an oncologic disorder and 112 (47%) non-oncologic; 120 (50%) had > 1 additional underlying medical condition (Table 1). Thirty (13%) IC case-patients were aged 8 months–4 years, 115 (48%) 5–11 years, and 94 (39%) 12–18 years. Life-threatening illness or death occurred in 1 (3%) IC case-patient aged 8 months–4 years, 8 (7%) aged 5–11 years , and 13 (14%) aged 12-18 years (including 2 deaths). Among 209 IC case-patients aged 5–18 years, 26 (23%) of those with oncologic and 27 (28%) with non-oncologic disorders had received 2 doses of a monovalent primary COVID-19 vaccine series; 6 (5%) and 14 (14%) had received > 3 doses, respectively (p=.03; Table 2). A significantly higher proportion of IC case-patients (n=73/209; 35%) had received at least 2 COVID-19 vaccine doses compared with non-IC patients (n=284/1021; 28%; p=0.04; Table 2). [Figure: see text] [Figure: see text] CONCLUSION: During Omicron, immunocompromised children hospitalized for COVID-19 were more frequently aged > 5 years and > 99% survived. Vaccination coverage was low among all case-patients. A higher proportion of IC children who received >2 vaccine doses were among those case-patients hospitalized for COVID-19 compared with non-IC children. Additional doses to improve protection in IC children are recommended. DISCLOSURES: Regina Simeone, PhD, Pfizer: Stocks/Bonds Natasha B. Halasa, MD, MPH, Merck: Grant/Research Support|Quidell: Grant/Research Support|Quidell: donation of kits|Sanofi: Grant/Research Support|Sanofi: vaccine support Oxford University Press 2023-11-27 /pmc/articles/PMC10679127/ http://dx.doi.org/10.1093/ofid/ofad500.531 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Campbell, Angela P Zambrano, Laura D Newhams, Margaret M Wu, Michael J Simeone, Regina Orzel, Amber Halasa, Natasha B Fleming-Dutra, Katherine E Randolph, Adrienne G 461. COVID-19 Hospitalizations among Vaccinated and Unvaccinated Immunocompromised Children, 23 States, December 2022 – April 2023 |
title | 461. COVID-19 Hospitalizations among Vaccinated and Unvaccinated Immunocompromised Children, 23 States, December 2022 – April 2023 |
title_full | 461. COVID-19 Hospitalizations among Vaccinated and Unvaccinated Immunocompromised Children, 23 States, December 2022 – April 2023 |
title_fullStr | 461. COVID-19 Hospitalizations among Vaccinated and Unvaccinated Immunocompromised Children, 23 States, December 2022 – April 2023 |
title_full_unstemmed | 461. COVID-19 Hospitalizations among Vaccinated and Unvaccinated Immunocompromised Children, 23 States, December 2022 – April 2023 |
title_short | 461. COVID-19 Hospitalizations among Vaccinated and Unvaccinated Immunocompromised Children, 23 States, December 2022 – April 2023 |
title_sort | 461. covid-19 hospitalizations among vaccinated and unvaccinated immunocompromised children, 23 states, december 2022 – april 2023 |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679127/ http://dx.doi.org/10.1093/ofid/ofad500.531 |
work_keys_str_mv | AT campbellangelap 461covid19hospitalizationsamongvaccinatedandunvaccinatedimmunocompromisedchildren23statesdecember2022april2023 AT zambranolaurad 461covid19hospitalizationsamongvaccinatedandunvaccinatedimmunocompromisedchildren23statesdecember2022april2023 AT newhamsmargaretm 461covid19hospitalizationsamongvaccinatedandunvaccinatedimmunocompromisedchildren23statesdecember2022april2023 AT wumichaelj 461covid19hospitalizationsamongvaccinatedandunvaccinatedimmunocompromisedchildren23statesdecember2022april2023 AT simeoneregina 461covid19hospitalizationsamongvaccinatedandunvaccinatedimmunocompromisedchildren23statesdecember2022april2023 AT orzelamber 461covid19hospitalizationsamongvaccinatedandunvaccinatedimmunocompromisedchildren23statesdecember2022april2023 AT halasanatashab 461covid19hospitalizationsamongvaccinatedandunvaccinatedimmunocompromisedchildren23statesdecember2022april2023 AT flemingdutrakatherinee 461covid19hospitalizationsamongvaccinatedandunvaccinatedimmunocompromisedchildren23statesdecember2022april2023 AT randolphadrienneg 461covid19hospitalizationsamongvaccinatedandunvaccinatedimmunocompromisedchildren23statesdecember2022april2023 |